Document Detail

Tenofovir use and pregnancy among women initiating HAART.
MedLine Citation:
PMID:  22951630     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Recent studies have raised concerns about a change in rates of pregnancy among HIV-negative women exposed to tenofovir. Here, our objective was to determine among HIV-positive women whether use of tenofovir at HAART initiation or thereafter is associated with subsequent changes in incidence of pregnancy.
DESIGN: Analysis of prospectively collected clinical data.
METHODS: We used Cox proportional hazards models and logistic regression to estimate hazard ratios and odds ratios for the association of baseline tenofovir use and first incident pregnancy. We used marginal structural Cox models to estimate hazard ratios for the association of current tenofovir use and time to first incident pregnancy.
RESULTS: We studied 7275 women, of whom 1199 were initiated on tenofovir-based HAART regimens, and who experienced a total of 894 pregnancies in 17,200 person-years of follow-up. Analyses showed slight reductions in hazards of pregnancy among women who used tenofovir but without sufficient precision to draw strong conclusions. Sensitivity analyses confirmed main results.
CONCLUSIONS: Tenofovir may be associated with a lower hazard or rate of pregnancy in women receiving HAART. However, conclusions are limited by low precision, the observational nature of the data, and possible uncontrolled confounding by temporal trends in contraception use and other factors.
Mhairi Maskew; Daniel Westreich; Cindy Firnhaber; Ian Sanne
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  AIDS (London, England)     Volume:  26     ISSN:  1473-5571     ISO Abbreviation:  AIDS     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-06-03     Revised Date:  2013-12-05    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  England    
Other Details:
Languages:  eng     Pagination:  2393-7     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenine / analogs & derivatives*,  pharmacology,  therapeutic use
Anti-HIV Agents / pharmacology,  therapeutic use*
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
Follow-Up Studies
HIV Seropositivity / drug therapy*,  epidemiology*
Infectious Disease Transmission, Vertical / prevention & control
Middle Aged
Organophosphonates / pharmacology,  therapeutic use*
Pregnancy Complications, Infectious / epidemiology*,  prevention & control
Proportional Hazards Models
Prospective Studies
Risk Assessment
South Africa / epidemiology
Treatment Outcome
Women's Health
Grant Support
4R00-HD-06-3961 03/HD/NICHD NIH HHS; NIH/NIAID2P3-AI-645 18//PHS HHS; R00 HD063961/HD/NICHD NIH HHS
Reg. No./Substance:
0/Anti-HIV Agents; 0/Organophosphonates; 107021-12-5/tenofovir; JAC85A2161/Adenine
Erratum In:
AIDS. 2013 Mar 13;27(5):855

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Features of twins and stacking faults in silver nanorice and electron-beam irradiation effect.
Next Document:  Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons.